sales price

recent valuation of ATC used a very conservative $3700 per patient per year
compare that to Isentress at $12 864 and do the sums on ATC near that price

AIDS Drug Initially Approved as a Salvage Therapy Gets FDA Nod for Use as First Line HIV Treatment, Which Vastly Expands Company’s US Market; Isentress Now the Most Expensive First Line Therapy

...

Currently, Isentress is up to three times more expensive than other first line antiretroviral treatments. Merck’s price per patient yearly (ppy) for the drug varies among the retail price and to certain government programs. Merck’s current retail price (Average Wholesale Price) for Isentress is $12,864 ppy — making it the most expensive of any antiretroviral recommended by HHS for therapy naive patients.

...
Merck’s goals in establishing the price for Isentress, including:

“Create broad patient access, including for patients who are covered by ADAP, Medicaid and private insurance” and “Generate an appropriate return on investment, based upon years of breakthrough research and the value Isentress brings to patients and healthcare providers, that will enable us to continue to pursue innovations through our research efforts”

Merck’s response also noted:

“…at a Wholesale Acquisition Cost (WAC) of $27 per day, it [Isentress] is priced comparably with ritonavir-boosted protease inhibitors, the most frequently prescribed therapy for treatment experienced patients.”

...

Merck’s initial pricing of Isentress was in essence pegged or ‘priced comparably’ to those of other second line and salvage therapies. Now that Isentress has cleared FDA approval for first line use — a far larger market share — we are asking Merck to lower the price of Isentress in line with prices for other first line treatments for therapy naive patients

http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20090724005637&newsLang=en